Drawing for IVERTAX

USPTO serial 99267704

IVERTAX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
STRASSLE, MARIANNE
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with IVERTAX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MAREK KRIZKA

MAREK KRIZKA TRAMA LEGAL, PLLC1178 BROADWAY, FLOOR 3NEW YORK, NY 10001UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Food supplements; Nutritional supplements; Dietary supplements; Herbal supplements; Vitamin and mineral supplements; Protein supplements; Probiotic supplements; Prebiotic supplements; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of infectious diseases; Preparations for destroying parasites; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of viral diseasesABANDONEDJan 1, 2025

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 4, 2026MAB4ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION—
Aug 4, 2026ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Aug 4, 2026OP.TOPPOSITION TERMINATED NO. 999999—
Aug 4, 2026OP.SOPPOSITION SUSTAINED NO. 999999—
May 13, 2026ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Mar 19, 2026OP.IOPPOSITION INSTITUTED NO. 999999—
Mar 17, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 17, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 17, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 11, 2026ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 13, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 13, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 7, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 13, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 21, 2025DOCKASSIGNED TO EXAMINER—
Nov 10, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 4, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 4, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance